Form 4: RAPT Therapeutics Director Scott Braunstein Granted 25,000 Stock Options

RAPT Therapeutics, Inc. Director Scott Braunstein was granted 25,000 stock options with an exercise price of $7.43, vesting over three years.

Summary

• Scott Braunstein, a Director of RAPT Therapeutics, Inc. (RAPT), was granted 25,000 Director Stock Options.
• The options have an exercise price of $7.43 per share.
• The grant date for these options is June 21, 2025.
• The options will vest in three successive equal annual installments over a three-year period, measured from the grant date of June 21, 2025.
• The options expire on June 21, 2035.
• Following this transaction, Mr. Braunstein beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event, but it aligns director interests with long-term shareholder value, which is generally viewed favorably.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term company performance and value creation.
• The options have a 10-year expiration period (until June 21, 2035), providing a substantial window for potential value realization.

Negatives

• No immediate negatives are apparent from a routine stock option grant, as it is a standard compensation mechanism.

Risks

• The value of the stock options is contingent on the future stock price of RAPT Therapeutics, Inc. exceeding the exercise price of $7.43.
• If the company's stock price does not increase above the exercise price, the options may expire worthless, providing no financial benefit to the holder.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and serves as a long-term incentive for company performance and shareholder value creation.

Industry Context

Stock option grants are a common and widely accepted form of executive and director compensation in the biotechnology and pharmaceutical industries, designed to align leadership incentives with long-term shareholder value creation and company growth.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across U.S. public companies, particularly prevalent in growth-oriented sectors like biotechnology, as a means of non-cash compensation.
• The vesting schedule of three equal annual installments over three years is a common and typical structure for long-term incentive plans, balancing director retention with performance incentives.
• A 10-year expiration period for stock options is also a standard duration for such equity grants in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact as the director's financial interests are further aligned with the company's stock price appreciation, incentivizing decisions that enhance shareholder value.

Next Steps

• The granted options will vest in three equal annual installments over the next three years, starting from June 21, 2025.
• Scott Braunstein may choose to exercise these options at any time after they vest and before their expiration date of June 21, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, RAPT, Scott Braunstein, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Beneficial Ownership